TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06699849: A Phase 2, Multicenter, Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Oc

Sponsor: CSL Behring · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 70 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$398,400

Rescue Site Savings

+$265,600

Unlock Full NCT06699849 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06699849 Rescue Dossier →